Abstract | Mild traumatic brain injury (TBI), which is defined as a head trauma resulting in a brief loss of consciousness and/or alteration of mental state, is usually benign, but occasionally causes persistent and sometimes progressive symptoms. Whether a threshold for the amount of brain injury and/or individual vulnerability might contribute to the development of these long-term consequences is unknown. Furthermore, reliable diagnostic methods that can establish whether a blow to the head has affected the brain (and in what way) are lacking. In this Review, we discuss potential biomarkers of injury to different structures and cell types in the CNS that can be detected in body fluids. We present arguments in support of the need for further development and validation of such biomarkers, and for their use in assessing patients with head trauma in whom the brain might have been affected. Specifically, we focus on the need for such biomarkers in the management of sports-related concussion, the most common cause of mild TBI in young individuals, to prevent long-term neurological sequelae due to concussive or subconcussive blows to the head. Zetterberg, H. et al. Nat. Rev. Neurol.
Introduction
A blow to the head can result in anything from a super ficial skin laceration to severe brain injury. The extremes of this range are easy to recognize by clinical examina tion and neuroimaging, but whether the brain has been injured by a blow to the head (in the presence of non specific symptoms such as dizziness, nausea or headache) is more difficult to assess. The definition of mild traumatic brain injury (TBI) has changed over the past 60 years, 1 but the American Congress of Rehabilitation Medicine currently defines mild TBI as head trauma resulting in one of the following: loss of consciousness for less than 30 min, alteration of mental state for up to 24 h (being dazed, confused or disorientated), or loss of memory for events immediately before or after the trauma. 2 The terms mild TBI and concussion have historically been used interchangeably to suggest an inconsequen tial injury; however, mild TBI is far from trivial, since it can induce selective swelling and disconnection of white matter axons. 3, 4 Furthermore, repeated episodes of mild TBI are associated with chronic and sometimes progressive clinical symptoms and neuropathological changes. 5 Although the mechanisms underlying the association between single or repetitive mild TBI and progressive neurodegeneration are not yet understood, we can reasonably assume that accurate biochemical tests of axonal, neuronal and astroglial injury would be helpful to indicate whether a person with head trauma has experienced an injury to the brain, to establish the severity and nature of the injury, and to identify when the injury has resolved.
The detection of brain injury in individuals who have experienced a concussive or subconcussive blow to the head is of particular relevance in sports such as boxing, hockey, rugby and American football. Head injuries are common in players of these sports, and several athletes' careers have ended because of chronic neurological or psychiatric symptoms. 6 An objective test to deter mine whether an athlete can safely return to their sport would, therefore, be highly desirable, and would reduce the current overreliance on CT scans (and the associ ated exposure to ionizing radiation) for this purpose Another group of individuals at risk of brain injury is military personnel, who might be exposed to several types of brain trauma in the battlefield. 7 In addition to bio markers for use in the acute and subacute phases of mild TBI, develop ment of biomarkers that will enable clinical studies of the potential neuropathological cas cades in the chronic phase of mild TBI is also important. This statement is valid not only for fluid biomarkers but also for imaging and other markers.
In this Review, we provide an overview of the current research on fluid biomarkers of mild TBI. We describe the biomarkers that are already in clinical use and those that require further development before they can be used in clinical practice.
in most patients, resolves in a spontaneous manner over a fairly short period of time. However, approximately 15% of individuals with mild TBI develop persistent cognitive dysfunction. 9, 10 Mild TBI is usually caused by an impact to the head (contact loading) that induces rotational acceleration of the brain (inertial loading). In some patients, mild TBI occurs without an impact to the head, such as after rapid rotational acceleration of the head in restrained occupants during a motor vehicle crash. 11 At a neurophysiological level, these mechanical and inertial forces result in the stretching of white matter axons, leading to diffuse axonal injury. 12 Although axonal disconnection rarely occurs at the time of injury, the rapid stretching of axons causes an unregulated flux in ion concentrations, including an efflux of K + and influx of Na + from and into the axon that, in turn, causes an increase in intraaxonal Ca 2+ con centrations. 13, 14 As the concentration of Ca 2+ increases, the protease calpain becomes activated, triggering calpainmediated proteolysis of cytoskeletal proteins, which might translate into irreversible axonal pathol ogy. 15 An increase in intraaxonal Ca 2+ concentration stimulates glutamate release and glutamatemediated activation of Nmethyldaspartate receptors, result ing in further depolarization of neurons. 16, 17 Increased activity of various membrane pumps to restore the ionic balance leads to increased glucose consumption, deple tion of energy stores, Ca 2+ influx into mitochondria, impaired oxidative metabolism, and glycolysis with lactate production, which causes acidosis and oedema.
In addition to these ionic disturbances, ultrastructural studies of axons show mechanical breakage and buckling of microtubules at the time of injury, which can trigger progressive microtubule disassembly. 18 These com bined pathological processes result in interruption of axonal transport and accumulation of protein products. This accumulation gives rise to the two classic neuro pathological phenotypes of axonal swelling: singular axonal bulbs (previously called retraction balls) and axonal varicosities, which occur as a series of protru sions along individual axons. 13, 19 At a critical threshold of axonal swelling, the axons disconnect at the location of the injury (secondary axotomy). 16, 17, 20, 21 Neuronal damage Key points ■ Biomarkers of neuronal, axonal and astroglial damage could be used to diagnose mild traumatic brain injury (TBI) and predict clinical outcomes of patients with head trauma ■ Such biomarkers could provide important information for medical counselling of at-risk individuals, such as military personnel and concussed athletes ■ Cerebrospinal fluid markers are preferred over peripheral blood markers, owing to their increased proximity to the brain and decreased susceptibility to the confounding effects of various extracerebral factors ■ Ultrasensitive assays are needed for reliable quantification of CNS-specific biomarkers in blood, as their concentrations are below the lower limit of detection by most standard immunoassays ■ Clinical studies of serial biomarker measurements in conjunction with advanced brain imaging during the acute and subacute phases of mild TBI are warranted ■ Longitudinal studies of biomarkers in patients with chronic or progressive symptoms after TBI might help to clarify the pathogenesis and clinical course of chronic traumatic encephalopathy consisting of axonal bulbs and swellings is most com monly located in the deep gyri at the interface between the grey and white matter. 13, 22 Studies using advanced MRI techniques, such as diffusion tensor imag ing, show that the extent of white matter abnormalities after mild TBI correlates with the severity of postconcussion co gnitive problems. [23] [24] [25] Many practicing clinicians have assumed that the axonopathy and metabolic stress in patients with mild TBI is reversed within 1-2 weeks, because this is when clini cal symptoms have most often disappeared. 26 How ever, magnetic resonance spectroscopy findings, electro physiological data and neuropsychological assessments suggest that patients' physiological parameters return to baseline after 30-45 days. 27, 28 Moreover, neuro pathological analyses indicate that axonopathy might continue for years after TBI. 13 Another important con sideration affecting the patient's recovery after mild TBI is their age, since the developing brain seems to be more vulnerable to repeated concussions than is the adult brain, 29 owing to differences in the degree of myelina tion, volume ratio of brain to water, elastic proper ties, and blood-brain barrier (BBB) integrity. 30, 31 This knowl edge, in conjunction with available biomechanical, radio logical and clinical data, 32, 33 should be communicated to parents with the aim of discouraging the participation of children in contact sports that target the head.
A form of TBIinduced early dementia was first reported in 1928 among professional boxers, years after their careers had ended. 34 Initially termed dementia pugilistica or punchdrunk syndrome, the prevalence of this neuropsychiatric manifestation is now estimated at around 20% in former professional boxers. 35, 36 These observations aroused great interest in the longterm out comes of patients who developed chronic or progressive symptoms after a single episode or repeated episodes of mild TBI. 37 Such symptoms can include changes in cognition (memory and executive functioning), mood (depression, apathy and suicidal thoughts), personality and behaviour (poor impulse control and behavioural disinhibition), and movement (including parkinsonism and symptoms of motor neuron dysfunction), which are similar to those described in exboxers. 38 Some investigators have started to describe this constel lation of symptoms as chronic traumatic encephalopathy (CTE); [39] [40] [41] however, vigorous debate is ongoing among researchers regarding the definition of CTE from both neuropsychiatr ic and neuropathological perspectives.
The brains of former boxers with CTE also display the hallmark pathologies of Alzheimer disease (AD), including neurofibrillary tangles composed of hyper phosphorylated tau and amyloidβ (Aβ) plaques. 42, 43 Progressive axonopathy in these patients might underlie the rapid formation of Aβ plaques after TBI. 44 The risk factors for CTE in exboxers are a long career, many bouts, high sparring exposure, many knockouts, poor perfor mance, and being able to tolerate many blows without being knocked out, all of which are associated with cumu lative exposure to repetitive brain trauma. 40 According to one study, a positive apolipoprotein E ε4 status, commonly associated with AD, is a risk factor for CTE in these indivi duals. 36 Similarly, tau and Aβ pathology, as well as TAR DNAbinding protein 43 (TDP43) deposition, have been found in the brains of patients with CTE approximately 10 years after professional participation in contact sports such as American football. 45 Notably, neuritic Aβ plaques and neurofibrillary tangles have also been found in patients a few years to four decades after a single episode of moderate or severe TBI. 46 However, TDP43 deposi tion was not found in these patients, suggesting that this pathological feature might be used to distinguish patients with CTE due to a single episode of TBI from those with CTE due to repetitive TBI. 47 Currently available fluid biomarkers CSF biomarkers of acute brain injury The cerebrospinal fluid (CSF) is in direct contact with the extracellular matrix in the brain, and its composi tion reflects biochemical changes that occur in this organ. 48 For these reasons, the CSF might be considered an optimal source of biomarkers of brain injury. Several CSF biomarkers of brain injury have already been estab lished, including proteins that indicate BBB integrity and neuroinflammation, as well as axonal, neuronal and astroglial damage, as described below ( Figure 1 , Table 1 ).
Blood-brain barrier integrity
The BBB, which is formed from the endothelial cells that line cerebral capillaries, has an important role in maintaining a regulated microenvironment for reliable neuronal signalling. 49 The CSF:serum albumin ratio is a standard biomarker of BBB function. 50 Albumin is mainly synthesized in the liver and, consequently, most albumin in CSF is derived from the blood via passage across the BBB. An increase in this ratio indicates BBB damage, which is found in patients with various CNS dis orders, such as infections, inflammatory diseases, brain tumours or cerebrovascular diseases. 48 Two studies have shown an increase in the CSF:serum albumin ratio in patients with severe TBI associated with a neuroinflammatory response. 51, 52 By contrast, no such changes have been seen in studies of mild TBI in boxers and military personnel with blast exposure, 53, 54 suggesting that the BBB remains intact in individuals with mild TBI.
Neuroinflammation
The findings of a large number of studies confirm that an acute inflammatory response occurs within the CNS after severe TBI, which is reflected in the concentra tions of various CSF components. 51, 52, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] In general, levels of inflammatory proteins, such as IL6, IL8 and IL10, are increased in CSF in response to severe TBI. The magnitude of the rise correlates with the patient's outcome, and in some studies also with the extent of BBB dysfunction, as shown by the CSF:serum albumin ratio. This rise is an important confounder, since inflamma tory protein levels in plasma are normally much higher than in CSF; passive leakage of inflammatory proteins across an impaired BBB may lead to elevated CSF levels in the absence of neuroinflammation. However, studies on markers of neuroinflammation in patients with mild TBI are lacking. Many of the studies listed above analysed samples of ventricular CSF, which has a different protein composition from lumbar CSF. This approach makes the results of these studies less relevant to patients with mild TBI, in whom CSF samples-if collected at all-tend to be obtained by lumbar puncture.
Acute axonal injury
The two bestestablished CSF biomarkers of axonal injury are total tau and neurofilament light polypeptide (NFL). These two proteins have distinct regional distri butions in the brain, which might be helpful in determin ing which areas of the brain have been affected by TBI: tau protein is highly expressed in thin, nonmyelinated axons of cortical interneurons, 65 whereas NFL is most abundant in the largecalibre myelinated axons that project into deeper brain layers and the spinal cord. 66 Initial studies of tau protein as a marker of TBI com pared total tau levels in ventricular CSF samples from patients with severe TBI, with the concentration of total tau in samples of CSF obtained by lumbar puncture from various control groups. These studies showed higher levels of total tau in the TBI group than in the control groups, 67 ,68 but did not consider that tau protein levels are normally higher in CSF obtained from brain ven tricles than in samples obtained by lumbar puncture. These molecules include NSE, SBPs and UCH-L1, which are all enriched in the neuronal cytoplasm. NFL is a biomarker of injury to large-calibre myelinated axons. Total tau is a biomarker of injury to thin nonmyelinated axons. APP and amyloid-β are produced in axon terminals and might be involved in synaptic activity and plasticity. Overproduction of amyloid-β in response to trauma could result in formation of diffuse amyloid plaques. Injury to astroglial cells may lead to release of S100-B and GFAP into the extracellular matrix, which might increase S100-B levels in both cerebrospinal fluid and blood. Astrogliosis and post-injury neuroinflammation can result in increased production of interleukins and cytokines. Integrity of the blood-brain barrier is indicated by the cerebrospinal fluid:serum albumin ratio. Abbreviations: APP, amyloid precursor protein; GFAP, glial fibrillary acidic protein; MBP, myelin basic protein; NFL, neurofilament light polypeptide; NSE, γ-enolase; SBPs, spectrin breakdown products; UCH-L1, ubiquitin carboxyl-terminal hydrolase isoenzyme L1.
Nevertheless, the consensus in the literature is that total tau protein levels in ventricular CSF correlate with lesion size and clinical outcome in patients with TBI, such that high levels are an indication of moresevere injury. 67, 68, 70 Studies in patients with mild TBI, such as amateur boxers, show elevated levels of total tau in CSF obtained by lumbar puncture 4-10 days after a bout, and similar results are found in boxers who have not been knocked out. 54, 71 Total tau protein levels in these individuals nor malize during the 8-12 weeks after a bout, provided that the boxer has not participated in any further bouts. 54, 71 Total tau protein levels in CSF might, therefore, serve as a marker of axonal damage in grey matter neurons.
Neurofilaments are composed of neuronspecific intermediate filaments. 72 Each intermediate filament consists of one light subunit (NFL) plus either a medium subunit (NFM) or a heavy subunit (NFH), arranged headtotail. 72 High levels of phosphorylated NFH have been demonstrated in the ventricular CSF of patients with severe TBI. 73 Similarly, high levels of NFL have been demonstrated in CSF samples obtained by lumbar punc ture from amateur boxers with mild TBI after a bout. 54, 71 The magnitude of the rise in NFL is larger than that for total tau protein, which suggests that mild TBI affects the long myelinated axons in white matter to a greater extent than it affects the short nonmyelinated axons in the cortex. 54, 71 NFL in CSF seems to be the most sensitive fluid biomarker of axonal injury to date. 54, 71 Interestingly, the levels of NFL in CSF obtained by lumbar puncture from amateur boxers correlate positively with their expo sure to head trauma, such as the number of hits to the head received, and subjective and objective estimates of the intensity of the fight.
54,71
Acute neuronal injury γEnolase (also known as NSE, or neuronspecific eno lase, despite its presence in erythrocytes, as well as in endocrine cells) is a glycolytic enzyme enriched in neu ronal cell bodies. 74 The level of NSE was initially analysed in serum and ventricular CSF obtained from patients with severe head trauma and coma, in whom this protein was identified as a promising marker of neuronal damage. 75 NSE levels in ventricular CSF corre late with mor tality after TBI (levels are higher in non survivors than in survivors) and/or with other TBI severity scores, such as the Glasgow Coma Scale and Glasgow Out come Score, in both adults and children. [76] [77] [78] [79] [80] Levels of NSE in CSF obtained by lumbar puncture have been suggested as a possible screening tool for inflicted TBI in children, 81 but studies on the levels of NSE in CSF samples obtained by lumbar puncture in patients with mild TBI are lacking. The main limitation of using NSE levels in CSF as a bio marker of neuronal injury is its high sensitivity to haemo lysis: NSE levels are markedly increased by in vitro lysis of erythrocytes derived from blood contamination of the sample. 82 
Acute astroglial injury
The S100 proteins are a family of Ca 2+ binding proteins that help to regulate intracellular levels of calcium. 74 The first S100 protein was identified in 1965, 83 and two related homodimeric proteins, S100A1 (which consists of two α subunits) and S100B (which consists of two β subunits), were subsequently identified. 84 An S100 αβ heterodimer also exists. 74 In the biomarker litera ture, most assays for S100 proteins do not differentiate between the ββ homodimer and the αβ heterodimer; however, in a study in which the different forms could be differentiated, they all showed similar profiles of release into serum after brain trauma.
85 S100B was previously thought to be specific to astrocytes, but has since been detected in oligodendrocytes and various extracerebral cell types; for example, chondrocytes and adipocytes. 74 S100B levels in peripheral blood have been examined extensively in patients with TBI, but studies of the levels of this potential biomarker in CSF are scarce. Amateur boxers have slightly elevated levels of S100B in CSF samples obtained by lumbar puncture after a bout, but the increase is not as pronounced as that observed in levels of the axonal markers total tau and NFL. 71 Similar results (that is, slightly elevated levels in CSF samples obtained by lumbar puncture from amateur boxers after a bout) have been reported for glial fibrillary acidic protein (GFAP), 54, 71 a CNSspecific intermediate filament protein that is almost exclusively expressed in astroglia. 74 The changes in GFAP levels after mild TBI are not as pronounced as the changes in total tau and NFL. 54, 71 However, when GFAP levels in ventricular CSF were evaluated in patients with severe TBI, the addition of this biomarker to clinical data improved the power of outcome prediction models. 86 Amyloid-related processes Studies in both animals and humans have demonstrated that amyloid precursor protein (APP) accumulates in neurons and axons after brain trauma that causes axonal damage. [87] [88] [89] [90] [91] In experimental models of TBI, accumu lation of APP occurs 2-3 h after the trauma and is also present in patients with mild TBI. 3, 92 In addition to the accumulation of APP, acute intraaxonal accumulation of Aβ is common in patients with TBI. [93] [94] [95] Aβ-in par ticular the Aβ 42 isoform, which is prone to aggregation and is associated with the development of AD-is sub sequently released into the tissue surrounding damaged axons, where it leads to plaque formation. [96] [97] [98] Ventricular CSF levels of Aβ 40 and Aβ 42 increase during the first week after head trauma in patients with severe TBI. 99 ,100 Similar results were found for soluble α and β isoforms of APP. 100 However, in samples of CSF obtained by lumbar puncture from patients with mild TBI, no changes in Aβ 40 or Aβ 42 were seen. 54, 71 These results suggest that Aβ levels in CSF samples obtained by lumbar puncture are less sensitive to the effects of mild TBI than are NFL and total tau levels.
Blood biomarkers of acute brain injury Some proteins that are highly expressed within the CNS are also detectable-albeit at very low concentra tions, owing to their dilution in the much larger plasma volume and extracellular matrix of peripheral tissues-in the peripheral blood. 101, 102 Since collection of peripheral blood samples is considerably easier than collection of CSF in routine clinical practice, many candidate CSF bio markers of mild TBI have also been assessed in periph eral blood ( Table 1) . The low concentration of potential biomarkers in peripheral blood is a technical limitation to the use of most standard immunoassays. However, the number of potential biomarkers of brain injury in periph eral blood is steadily increasing as the analytical tools for their detection become ever more sensitive. 103 A number of other obstacles to the development of reliable blood biomarkers of mild TBI exist. The BBB, though not as absolute a barrier as the name might suggest, 49 hinders the assessment of biochemical changes in the brain by use of biomarkers in the blood (impaired BBB integrity, however, as seen in severe TBI, can increase the levels of brainderived proteins in the blood). In addition, some potential markers undergo proteolytic degradation in blood, and their levels might be affected by clearance from blood via the liver or kidney. The precision of immunoassays can also be affected by binding of potential biomarkers to carrier pro teins, and by extracerebral sources of potential bio markers. As a consequence, reliable blood biomarkers of neurodegenerative processes (such as those taking place in patients with AD or in the presence of advanced neuro pathology) have been extremely difficult to iden tify. 48 Nevertheless, the literature on potential peripheral blood biomarkers of brain injury in patients with severe TBI is abundant. 104 Astroglial injury S100B and GFAP have both received considerable attention as peripheral blood markers of astroglial injury. Two reviews of biomarkers for TBI report that the levels of S100B and GFAP in serum are increased in patients with TBI and correlate with Glasgow Coma Scale scores and neuroradiological findings at hospital admission. 104, 105 These findings could help to differen tiate patients with mild TBI from those with severe TBI, and improve predictions of their outcome. 104, 105 However, S100B is also expressed in extracerebral cell types, including adipocytes and chondrocytes. 74 For this reason, some researchers have expressed concern that the observed increase in serum levels of S100B in patients with TBI might be attributable to release of this protein by damaged peripheral tissues, such as fractured bones or injured skeletal muscles. Indeed, elevated serum levels of S100B have been observed in both patients with multiple trauma and athletes without head injuries. [106] [107] [108] [109] [110] Moreover, serum S100B levels may increase in response to BBB dysfunction. 111 GFAP might be a better biomarker of mild TBI than is S100B, because extracerebral expression of GFAP has not been detected. A study of patients with mild TBI and abnormal findings on CT or MRI of the brain showed elevated serum levels of GFAP. 112 However, these marker levels did not predict patients' outcomes at 6 months postTBI.
Axonal and neuronal injury
Other candidate peripheral blood biomarkers of TBI are NSE, myelin basic protein (MBP) and hyper phosphorylated NFH, although no studies on MBP as a CSF biomarker are currently available. The increase in levels of NSE in CSF observed in response to lysis of erythrocytes is a major limitation of this biomarker in peripheral blood as well as in CSF. MBP levels might be a more specific marker of TBI than are NSE levels (specificity 96% versus 64%, respectively), but its sen sitivity is suboptimal (44% for MBP versus 71% for NSE). 113 Levels of NFH in serum samples taken from patients with severe TBI increased over 6 consecutive days in patients who eventually died from their injury, but levels of S100B increased more rapidly than those of NFH. 114 However, clinically important differences in biomarker release profiles might also be relevant. For example, NFH levels in serum remained elevated at days 2-4 postinjury in children with TBI who had a poor prognosis, whereas an early drop in serum NFH levels was predictive of improved outcome. 115 In a case study, serum concentrations of NFH were initially very high in a patient with fatal TBI induced by severe blast exposure. 116 Serum levels of NFH also seem to be fairly independent of BBB integrity. 112 Amyloid-related processes An ultrasensitive digital immunoassay has been devel oped for quantification of the CNSspecific protein tau in serum. 102 Serum levels of tau protein could be measured with a lower limit of detection of 0.02 pg/ml, and ranged from <10 pg/ml to 400 pg/ml in patients who were resus citated after cardiac arrest; the pattern of changes in serum levels of this protein observed over time correlated with outcome. 102 Two peaks in serum concentration were detected: one within the first 24 h after resuscitation, which was seen in almost all patients, and another after 24-48 h. The second peak was highest in patients who eventually died from their injury. 114 This is a sensitive detection method and could be useful in the context of mild TBI; further studies are warranted.
Novel fluid biomarkers
A number of potential biomarkers in CSF show increases in levels that correlate with the severity of the brain injury and with predicted outcomes. Longitudinal clinical studies in patients with mild TBI are needed, however, to understand how these biomarkers could be implemented in clinical practice.
Spectrin α chain, nonerythrocytic 1 (also known as αII spectrin) is primarily found in neurons, and is abun dantly expressed in axons and presynaptic terminals. 117 αII Spectrin is broken down by calpain and caspase3, which are upregulated in TBI during neuronal necro sis and apoptosis, respectively. Spectrin breakdown products have, therefore, been investigated as potential biomarkers of brain injury in rats and humans. 118, 119 The levels of spectrin breakdown products in ven tricular CSF samples from patients with severe TBI are associated with clinical correlates of the severity of the brain injury, such as Glasgow Coma Scale scores, and could be used to improve the prediction of patient outcomes. 86, 120, 121 For example, in one of these studies, levels of spectrin breakdown products in CSF were meas ured together with those of another potential marker, UCHL1 (ubiquitin carboxylterminal hydrolase iso enzyme L1), 86 a deubiquitinase that is highly expressed in neurons. 122 Levels of these two markers contributed clinically relevant prognostic information, in addition to that obtained by routine clinical assessments (such as the International Mission for Progress and Analysis of Clinical Trials in TBI prognostic calculator and the Glasgow Coma Scale). 120, 121 UCHL1 and spectrin breakdown product levels increase in a manner similar to S100B and GFAP in terms of correlation with other measures of the severity of TBI, as well as clinical outcome. 104 These breakdown products have also been studied in peripheral blood.
86
UCHL1 levels in blood are, however, increased by com promised BBB integrity. 112 As yet, there are no conclu sive studies on the potential diagnostic performance of UCHL1 and spectrin breakdown products as peripheral blood biomarkers in patients with mild TBI, but one pro spective cohort study of 96 patients with mild to mod erate TBI showed that UCHL1 is detectable in serum within 1 h of injury and that its level is associated with measures of injury severity, including the Glasgow Coma Scale score, lesions seen on brain imaging, and the need for neurosurgical intervention. 123 Proteomic analysis of potential new CSF biomarkers for TBI has not yet identified any such markers that can be used in clinically useful tests. 124 A number of proteo mics studies on potential biomarkers of TBI in periph eral blood have been published. These studies have replicated the findings from targeted analyses of speci fic candidate biomarkers, but as yet none of the novel biomarker profiles identified in these studies as being associated with TBI has been validated in independent studies using unrelated, nonproteomic or genomic tech niques. 104 Exciting preliminary data on the expression profiles of small noncoding RNAs in peripheral blood mononuclear cells from military personnel exposed to mild TBI have been reported; three small RNAs seem to be primarily associated with mild TBI, but the results require replication. 125 
Fluid biomarkers of chronic injury

Phosphorylated tau
The most prominent neuropathological characteris tic of CTE, as reported in studies of former boxers in the 1970s, is neurofibrillary tangles in cortical areas. 126 The bestestablished CSF biomarker to date for tangle pathology, at least in patients with AD, is phosphoryl ated tau. 48 However, some patients with chronic neuro degenerative diseases characterized by abundant tangle pathology-for example, Pick disease and progressive supranuclear palsy 127 -often have normal CSF levels of phosphorylated tau. 128, 129 The reason for this discrepancy is at present unknown, but one possible explanation is that the various tauopathies might involve different iso forms of aggregated tau 130 that are not detected in equal measure by all assays. The presence and levels of hyper phosphorylated tau isoforms in CSF have not yet been examined in patients with CTE.
TDP-43
Another pathological feature of CTE, namely, inclu sions of TDP43 in neurons and glial cells, 47, 131, 132 is also typical of frontotemporal dementia and amyotrophic lateral sclerosis. 133 TDP43 accumulation in patients with CTE can be widespread and is found in several grey matter structures, such as the brainstem, basal ganglia and cortical areas, as well as in subcortical white matter. 47, 132 Although assays for measuring TDP43 levels in CSF have been developed, 134 no studies have yet been publish ed on their use in patients with CTE.
Pituitary hormones
The prevalence of chronic pituitary dysfunction, caused by tearing of axons in the pituitary stalk, may be as high as 30-80% in patients 24-36 months after TBI. 135 Abnormalities in pituitary hormone levels correlate with the presence of longterm cognitive symptoms after TBI. 135 As these hormone disturbances are treat able by hormone replacement therapy, it is important to identify them and monitor the treatment through the measureme nt of pituitary hormone levels.
Interestingly, the occurrence of pituitary dysfunc tion bears no clear relationship with the severity of TBI. 135 MildTBIrelated chronic pituitary dysfunction has been reported in boxers and kickboxers subjected to repetitive head injury. In a preliminary study, 45% of professional boxers had growth hormone deficiency, although no other pituitary hormone deficiencies were observed. 136 In a large study of active and retired boxers, 18% had pituitary hormone deficiencies in one or more of the hypothalamic-pituitary-adrenal and growth hormone-insulinlike growth factor1 axes. 137 An inves tigation of pituitary dysfunction in amateur kickboxers revealed deficiencies in growth hormone and/or adreno corticotropin in 27% of the athletes. 138 In another study, the concentrations of 12 pituitary and targetorgan hormones were measured in two groups of male US combat ve terans. Abnormal levels of at least one pituitary hormone were detected in 11 of the 26 participants who had a history of blastinduced concussion. 139 
Conclusions
A large number of biomarkers of injury to different cell types and structures within the CNS can be detected in CSF and peripheral blood. This Review identifies a number of areas in which further research is needed to establish biomarkers of mild TBI. Several of the bio marker candidates were initially investigated in relation to severe TBI, in which setting they provide clinically relevant information and help to predict patient out comes. However, longitudinal studies of biomarker levels in patients with clinically relevant mild TBI are scarce. In the absence of such studies, it is difficult to suggest detailed diagnostic algorithms that incorporate fluid biomarkers for use in this setting. The lack of standard ized methods to quantify the available biomarkers also precludes the use of validated biomarker cutoff levels to guide clinical decisionmaking. Achieving validation of such cutoff points is an important goal of current research into biomarkers of mild TBI.
Axons seem to be the structures most vulnerable to damage from mild TBI, and reliable identification of peripheral blood biomarkers for axonal damage is needed. Tau protein and neurofilament proteins are promising biomarkers, but analytical techniques for measurement of this class of biomarkers in blood need to improve in sensitivity, beyond that usually achieved using conven tional immuno assays. Apart from assays for S100B and NSE, clinical assays for quantification of most bio markers do not yet exist, and no certified reference ma terials or methods for assay calibration are available. Improved animal models that reflect the relevant processes in mild TBI in humans, and in which new novel bio markers might be identified and evaluated, are also needed. Important advances in this regard have been made in the development of a mouse model of blastinduced neuro trauma, which seems to recapitulate key features of the neuro pathology seen in humans with mild TBI. 7 A critical challenge in research on the relationship between mild TBI and CTE is the ability to diagnose CTE in living patients. Identification of biomarkers of the neuropathological characteristics of CTE would make it possible to address whether or not individuals exposed to repetitive head trauma are at increased risk of CTE, and whether the extent of this risk can be determined via biomarker levels. The possible existence of a threshold for exposure to repetitive head injury resulting in CTE needs to be resolved, and the contribution of individual vulnerability to the risk of developing CTE also needs to be clarified. Identification of suitable biomarkers could potentially also help to identify preclinical CTE and shed light on whether the pathological process can be halted by appropriate treatment.
Review criteria
We searched PubMed for articles in the English language on traumatic brain injury using the keywords "TBI" or "traumatic brain injury", in combination with "biomarkers", "CSF", "plasma", "serum", "blood", "mild traumatic brain injury", and "chronic traumatic encephalopathy".
